Search by Drug Name or NDC

    NDC 30237-8900-06 PROVENGE 50000000 1-Jan Details

    PROVENGE 50000000 1-Jan

    PROVENGE is a INTRAVENOUS INJECTION in the CELLULAR THERAPY category. It is labeled and distributed by Dendreon Pharmaceuticals LLC. The primary component is SIPULEUCEL-T.

    Product Information

    NDC 30237-8900
    Product ID 30237-8900_0800e936-4297-61d4-e063-6394a90a74b1
    Associated GPIs 21651070001820
    GCN Sequence Number 066330
    GCN Sequence Number Description sipuleucel-T/lactated ringers PLAST. BAG 50 MM/250 INTRAVEN
    HIC3 V3H
    HIC3 Description ANTINEOPLASTIC - IMMUNOTHERAPY, THERAPEUTIC VAC
    GCN 28559
    HICL Sequence Number 036966
    HICL Sequence Number Description SIPULEUCEL-T/LACTATED RINGERS SOLUTION
    Brand/Generic Brand
    Proprietary Name PROVENGE
    Proprietary Name Suffix n/a
    Non-Proprietary Name sipuleucel-T
    Product Type CELLULAR THERAPY
    Dosage Form INJECTION
    Route INTRAVENOUS
    Active Ingredient Strength 50000000
    Active Ingredient Units 1-Jan
    Substance Name SIPULEUCEL-T
    Labeler Name Dendreon Pharmaceuticals LLC
    Pharmaceutical Class Autologous Cellular Immunotherapy [EPC], Cell-mediated Immunity [PE], Cells, Cultured, Autologous [EXT], Leukocytes, Mononuclear [CS]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA125197
    Listing Certified Through 2024-12-31

    Package

    NDC 30237-8900-06 (30237890006)

    NDC Package Code 30237-8900-6
    Billing NDC 30237890006
    Package 1 BAG in 1 CARTON (30237-8900-6) / 1 INJECTION in 1 BAG (30237-8900-5)
    Marketing Start Date 2010-04-29
    NDC Exclude Flag N
    Pricing Information N/A